Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2014
June 2014, Vol 5, No 5
June 2014, Vol 5, No 5
Value Propositions
Value Propositions
,
Value Peer-spectives
June 2014, Vol 5, No 5
Value Propositions from June 2014.
Read Article
Palonosetron Receives New Indication for CINV Prevention in Pediatric Patients
FDA Approvals, News & Updates
June 2014, Vol 5, No 5
Palonosetron HCl (Aloxi; Eisai) injection received a new US Food and Drug Administration (FDA) indication for the prevention of acute chemotherapy-induced nausea and vomiting (CINV) associated with initial or repeated courses of emetogenic chemotherapy in children aged 1 month to
Read Article
Ramucirumab First FDA-Approved Drug for Advanced Stomach Cancer after Chemotherapy
FDA Approvals, News & Updates
June 2014, Vol 5, No 5
The US Food and Drug Administration (FDA) approved ramucirumab (Cyramza; Eli Lilly) for the treatment of patients with advanced stomach cancer or gastroesophageal junction adenocarcinoma, which mostly affects older adults.
Read Article
Ofatumumab Approved for Chronic Lymphocytic Leukemia
FDA Approvals, News & Updates
June 2014, Vol 5, No 5
The US Food and Drug Administration approved ofatumumab (Arzerra Injection, GlaxoSmithKline) in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia, for whom fludarabine-based therapy is considered inappropriate.
Read Article
Oncology Organizations Follow the Association for Value-Based Cancer Care’s Lead on Value Discussions
By
Craig Deligdish, MD
From the Editor
,
Value Peer-spectives
June 2014, Vol 5, No 5
May was a busy month for those who have made a commitment to addressing cost, quality, and value in cancer care. The Association for Value-Based Cancer Care (AVBCC) held its Fourth Annual Conference in Los Angeles, CA.
Read Article
Enzalutamide Improves Survival After ADT in Patients with Metastatic CRPC
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
June 2014, Vol 5, No 5
Orlando, FL—Treatment with enzalutamide (Xtandi) after progression with androgen-deprivation therapy (ADT) led to a significant improvement in survival for men with metastatic castration-resistant prostate cancer (mCRPC), according to a new randomized trial reported at the 2014 American Urological Association annual meeting.
Read Article
Getting to Value in Cancer Care: The Time to Have That Conversation Is Now
By
Dana Butler
ASCO 2014 Highlights
,
Cancer Care
,
ASCO
June 2014, Vol 5, No 5
Chicago, IL—The question of value in oncology continues to pose challenges for oncologists and payers alike, as the costs of therapy continue to rise and health plans are wrestling with the need to design insurance coverage that promotes value.
Read Article
AVBCC Expert Panel: Impact of Personalized Medicine on Future and Current Therapies
By
Wayne Kuznar
June 2014, Vol 5, No 5
Los Angeles, CA—Increasing complexities in diagnostic science, the development of precision medicine, and the use of targeted agents require unprecedented levels of collaboration between pharmaceutical manufacturers, government agencies, and payers, said oncology experts during a panel discussion on personalized medicine at the Fourth Annual Conference of the Association for Value-Based Cancer Care.
Read Article
Oncologists Cite Lack of Resources and Time as Barriers to Addressing Cost Issues with Patients
By
Mark Knight
ASCO 2014 Highlights
,
ASCO
June 2014, Vol 5, No 5
Chicago, IL—Although the majority of oncologists believe that discussing the costs of care with the patient is important, many report a lack of resources available to them to inform cost-benefit decisions and a lack of time to discuss these issues with patients.
Read Article
Tafinlar (Dabrafenib)/Mekinist (Trametinib) Combination Therapy Received Accelerated FDA Approval for the Treatment of Patients with Metastatic Melanoma
By
Loretta Fala
Drug Updates
June 2014, Vol 5, No 5
Cutaneous melanoma, an aggressive form of skin cancer that develops in the melanocytes of the skin, is becoming increasingly prevalent in the United States.
Read Article
Page 1 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma